Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2019-07-05
Target enrollment:
Participant gender:
Summary
The objective of this study was to evaluate efficacy and safety of regorafenib in patients
with advanced liver cancer who had progressed after sorafenib treatment. Patients were
treated with regorafenib or placebo using a 2:1 randomization scheme.